Search

Your search keyword '"Himbert, D"' showing total 14 results
Start Over Author "Himbert, D" Database OAIster
14 results on '"Himbert, D"'

1. Effects of tricuspid transcatheter edge-to-edge repair on tricuspid annulus diameter - Data from the TriValve registry

Author

Russo, G, Hahn, R, Alessandrini, H, Andreas, M, Badano, L, Braun, D, Connelly, K, Denti, P, Estevez-Loureiro, R, Fam, N, Gavazzoni, M, Hausleiter, J, Himbert, D, Kalbacher, D, Latib, A, Lubos, E, Ludwig, S, Lurz, P, Monivas, V, Nickenig, G, Pedicino, D, Pedrazzini, G, Pozzoli, A, Praz, F, Rodes-Cabau, J, Rommel, K, Schofer, J, Sievert, H, Tang, G, Thiele, H, Unterhuber, M, von Bardeleben, R, Webb, J, Windecker, S, Leon, M, Maisano, F, Taramasso, M, Russo G., Hahn R. T., Alessandrini H., Andreas M., Badano L. P., Braun D., Connelly K. A., Denti P., Estevez-Loureiro R., Fam N., Gavazzoni M., Hausleiter J., Himbert D., Kalbacher D., Latib A., Lubos E., Ludwig S., Lurz P., Monivas V., Nickenig G., Pedicino D., Pedrazzini G., Pozzoli A., Praz F., Rodes-Cabau J., Rommel K. -P., Schofer J., Sievert H., Tang G., Thiele H., Unterhuber M., von Bardeleben R. S., Webb J., Windecker S., Leon M., Maisano F., Taramasso M., Russo, G, Hahn, R, Alessandrini, H, Andreas, M, Badano, L, Braun, D, Connelly, K, Denti, P, Estevez-Loureiro, R, Fam, N, Gavazzoni, M, Hausleiter, J, Himbert, D, Kalbacher, D, Latib, A, Lubos, E, Ludwig, S, Lurz, P, Monivas, V, Nickenig, G, Pedicino, D, Pedrazzini, G, Pozzoli, A, Praz, F, Rodes-Cabau, J, Rommel, K, Schofer, J, Sievert, H, Tang, G, Thiele, H, Unterhuber, M, von Bardeleben, R, Webb, J, Windecker, S, Leon, M, Maisano, F, Taramasso, M, Russo G., Hahn R. T., Alessandrini H., Andreas M., Badano L. P., Braun D., Connelly K. A., Denti P., Estevez-Loureiro R., Fam N., Gavazzoni M., Hausleiter J., Himbert D., Kalbacher D., Latib A., Lubos E., Ludwig S., Lurz P., Monivas V., Nickenig G., Pedicino D., Pedrazzini G., Pozzoli A., Praz F., Rodes-Cabau J., Rommel K. -P., Schofer J., Sievert H., Tang G., Thiele H., Unterhuber M., von Bardeleben R. S., Webb J., Windecker S., Leon M., Maisano F., and Taramasso M.

Abstract

Aims: T-TEER is an effective therapy for the treatment of tricuspid regurgitation (TR). However, the effects of leaflets clipping on tricuspid valve annulus (TA) have not been investigated in detail. The aim of this study is to investigate the effects of tricuspid transcatheter edge-to-edge repair (T-TEER) on TA diameter. Methods and results: The TriValve registry (Transcatheter Tricuspid Valve Therapies, NCT03416166) collected 556 patients from 22 European and North American centres undergoing transcatheter tricuspid valve interventions from 2016 to 2022. Patients undergoing T-TEER with available pre- and post-procedural data on TA diameter measured in the apical 4-chamber view on transthoracic echocardiography were selected for this study. Primary end-point was the reduction of TA diameter after T-TEER. A total of 186 patients were included in the study. In 115 patients (62%) TA diameter was reduced by at least 1 mm as compared to baseline. A significant reduction of TA dimension was observed following T-TEER (mean 2.3 mm [from pre-procedural diameter 46.7 mm to post-procedural diameter 44.4 mm], p < 0.001). In particular, the greatest reduction was observed in those with T-TEER in antero-septal commissure (mean 2.7 mm [from 47.1 mm to 44.4 mm], p < 0.001) as compared to those combining both antero-septal and postero-septal commissures (mean 1.4, from 46.0 mm to 44.6 mm, P = 0.06). A significant reduction of TA dimension was recorded in patients with 1 or 2 clips implanted but not in those patients with ≥3 clips implanted. Conclusions: In almost two third of patients T-TEER reduces TA diameter in addition to leaflet approximation. Condensed abstract: The effects of tricuspid transcatheter edge-to-edge repair (T-TEER) on tricuspid valve annulus (TA) have not been studied in details. This study investigates TA diameter as measured in apical 4-chamber view on transthoracic echocardiography before and after T-TEER. A total of 186 patients from the TriValve regis

Published
2024

2. Prognostic Implications of Residual Tricuspid Regurgitation Grading After Transcatheter Tricuspid Valve Repair

Author

Dreyfus, J, Taramasso, M, Kresoja, K, Omran, H, Iliadis, C, Russo, G, Weber, M, Nombela-Franco, L, Estevez Loureiro, R, Hausleiter, J, Latib, A, Stolz, L, Praz, F, Windecker, S, Zamorano, J, von Bardeleben, R, Tang, G, Hahn, R, Lubos, E, Webb, J, Schofer, J, Fam, N, Lauten, A, Pedrazzini, G, Rodes-Cabau, J, Nejjari, M, Badano, L, Alessandrini, H, Himbert, D, Sievert, H, Piayda, K, Donal, E, Modine, T, Nickenig, G, Pfister, R, Rudolph, V, Bernick, J, Wells, G, Bax, J, Lurz, P, Enriquez-Sarano, M, Maisano, F, Messika-Zeitoun, D, Ajmone-Marsan, N, Bartko, P, Bazire, B, Benfari, G, Bohbot, Y, Carnero-Alcazar, M, Chan, V, Coisne, A, Crestanello, J, De Bonis, M, Doguet, F, Eggenspieler, F, Eixeres-Esteve, A, Loureiro, R, Eyharts, D, Flagiello, M, Galloo, X, Gavazzoni, M, Habib, G, Heitzinger, G, Iung, B, Juarez-Casso, F, Lavie-Badie, Y, Le Tourneau, T, Lim, P, Mbaki, Y, Michelena, H, Muraru, D, Nicol, M, Obadia, J, Radu, C, El Idrissi, K, Riant, E, Ruf, T, Sala, A, Selton-Suty, C, Senage, T, Tomasi, J, Topilsky, Y, Tribouilloy, C, Viau, F, Dreyfus J., Taramasso M., Kresoja K. -P., Omran H., Iliadis C., Russo G., Weber M., Nombela-Franco L., Estevez Loureiro R., Hausleiter J., Latib A., Stolz L., Praz F., Windecker S., Zamorano J. L., von Bardeleben R. S., Tang G. H. L., Hahn R., Lubos E., Webb J., Schofer J., Fam N., Lauten A., Pedrazzini G., Rodes-Cabau J., Nejjari M., Badano L., Alessandrini H., Himbert D., Sievert H., Piayda K., Donal E., Modine T., Nickenig G., Pfister R., Rudolph V., Bernick J., Wells G. A., Bax J., Lurz P., Enriquez-Sarano M., Maisano F., Messika-Zeitoun D., Ajmone-Marsan N., Bartko P., Bazire B., Benfari G., Bohbot Y., Carnero-Alcazar M., Chan V., Coisne A., Crestanello J., De Bonis M., Doguet F., Eggenspieler F., Eixeres-Esteve A., Loureiro R. E., Eyharts D., Flagiello M., Galloo X., Gavazzoni M., Habib G., Heitzinger G., Iung B., Juarez-Casso F., Lavie-Badie Y., Le Tourneau T., Lim P., Mbaki Y., Michelena H., Muraru D., Nicol M., Obadia J. -F., Radu C., El Idrissi K. R., Riant E., Ruf T., Sala A., Selton-Suty C., Senage T., Tomasi J., Topilsky Y., Tribouilloy C., Viau F., Dreyfus, J, Taramasso, M, Kresoja, K, Omran, H, Iliadis, C, Russo, G, Weber, M, Nombela-Franco, L, Estevez Loureiro, R, Hausleiter, J, Latib, A, Stolz, L, Praz, F, Windecker, S, Zamorano, J, von Bardeleben, R, Tang, G, Hahn, R, Lubos, E, Webb, J, Schofer, J, Fam, N, Lauten, A, Pedrazzini, G, Rodes-Cabau, J, Nejjari, M, Badano, L, Alessandrini, H, Himbert, D, Sievert, H, Piayda, K, Donal, E, Modine, T, Nickenig, G, Pfister, R, Rudolph, V, Bernick, J, Wells, G, Bax, J, Lurz, P, Enriquez-Sarano, M, Maisano, F, Messika-Zeitoun, D, Ajmone-Marsan, N, Bartko, P, Bazire, B, Benfari, G, Bohbot, Y, Carnero-Alcazar, M, Chan, V, Coisne, A, Crestanello, J, De Bonis, M, Doguet, F, Eggenspieler, F, Eixeres-Esteve, A, Loureiro, R, Eyharts, D, Flagiello, M, Galloo, X, Gavazzoni, M, Habib, G, Heitzinger, G, Iung, B, Juarez-Casso, F, Lavie-Badie, Y, Le Tourneau, T, Lim, P, Mbaki, Y, Michelena, H, Muraru, D, Nicol, M, Obadia, J, Radu, C, El Idrissi, K, Riant, E, Ruf, T, Sala, A, Selton-Suty, C, Senage, T, Tomasi, J, Topilsky, Y, Tribouilloy, C, Viau, F, Dreyfus J., Taramasso M., Kresoja K. -P., Omran H., Iliadis C., Russo G., Weber M., Nombela-Franco L., Estevez Loureiro R., Hausleiter J., Latib A., Stolz L., Praz F., Windecker S., Zamorano J. L., von Bardeleben R. S., Tang G. H. L., Hahn R., Lubos E., Webb J., Schofer J., Fam N., Lauten A., Pedrazzini G., Rodes-Cabau J., Nejjari M., Badano L., Alessandrini H., Himbert D., Sievert H., Piayda K., Donal E., Modine T., Nickenig G., Pfister R., Rudolph V., Bernick J., Wells G. A., Bax J., Lurz P., Enriquez-Sarano M., Maisano F., Messika-Zeitoun D., Ajmone-Marsan N., Bartko P., Bazire B., Benfari G., Bohbot Y., Carnero-Alcazar M., Chan V., Coisne A., Crestanello J., De Bonis M., Doguet F., Eggenspieler F., Eixeres-Esteve A., Loureiro R. E., Eyharts D., Flagiello M., Galloo X., Gavazzoni M., Habib G., Heitzinger G., Iung B., Juarez-Casso F., Lavie-Badie Y., Le Tourneau T., Lim P., Mbaki Y., Michelena H., Muraru D., Nicol M., Obadia J. -F., Radu C., El Idrissi K. R., Riant E., Ruf T., Sala A., Selton-Suty C., Senage T., Tomasi J., Topilsky Y., Tribouilloy C., and Viau F.

Abstract

Background: The safety profile of transcatheter tricuspid valve (TTV) repair techniques is well established, but residual tricuspid regurgitation (TR) remains a concern. Objectives: The authors sought to assess the impact of residual TR severity post–TTV repair on survival. Methods: We evaluated the survival rate at 2 years of 613 patients with severe isolated functional TR who underwent TTV repair in TRIGISTRY according to the severity of residual TR at discharge using a 3-grade (mild, moderate, and severe) or 4-grade scheme (mild, mild to moderate, moderate to severe, and severe). Results: Residual TR was none/mild in 33%, moderate in 52%, and severe in 15%. The 2-year adjusted survival rates significantly differed between the 3 groups (85%, 70%, and 44%, respectively; restricted mean survival time [RMST]: P = 0.0001). When the 319 patients with moderate residual TR were subdivided into mild to moderate (n = 201, 33%) and moderate to severe (n = 118, 19%), the adjusted survival rate was also significantly different between groups (85%, 80%, 55%, and 44%, respectively; RMST: P = 0.001). Survival was significantly lower in patients with moderate to severe residual TR compared to patients with mild to moderate residual TR (P = 0.006). No difference in survival rates was observed between patients with no/mild and mild to moderate residual TR (P = 0.67) or between patients with moderate to severe and severe residual TR (P = 0.96). Conclusions: The moderate residual TR group was heterogeneous and encompassed patients with markedly different clinical outcomes. Refining TR grade classification with a more granular 4-grade scheme improved outcome prediction. Our results highlight the importance of achieving a mild to moderate or lower residual TR grade during TTV repair, which could define a successful intervention.

Published
2024

3. Prediction of Mortality and Heart Failure Hospitalization After Transcatheter Tricuspid Valve Interventions: Validation of TRISCORE

Author

Adamo, M, Russo, G, Pagnesi, M, Pancaldi, E, Alessandrini, H, Andreas, M, Badano, L, Braun, D, Connelly, K, Denti, P, Estevez-Loureiro, R, Fam, N, Gavazzoni, M, Hahn, R, Harr, C, Hausleiter, J, Himbert, D, Kalbacher, D, Ho, E, Latib, A, Lubos, E, Ludwig, S, Lupi, L, Lurz, P, Monivas, V, Nickenig, G, Pedicino, D, Pedrazzini, G, Pozzoli, A, Marafon, D, Pastorino, R, Praz, F, Rodes-Cabau, J, Besler, C, Schober, A, Schofer, J, Scotti, A, Piayda, K, Sievert, H, Tang, G, Sticchi, A, Messika-Zeitoun, D, Thiele, H, Schlotter, F, von Bardeleben, R, Webb, J, Dreyfus, J, Windecker, S, Leon, M, Maisano, F, Metra, M, Taramasso, M, Adamo M., Russo G., Pagnesi M., Pancaldi E., Alessandrini H., Andreas M., Badano L. P., Braun D., Connelly K. A., Denti P., Estevez-Loureiro R., Fam N., Gavazzoni M., Hahn R. T., Harr C., Hausleiter J., Himbert D., Kalbacher D., Ho E., Latib A., Lubos E., Ludwig S., Lupi L., Lurz P., Monivas V., Nickenig G., Pedicino D., Pedrazzini G., Pozzoli A., Marafon D. P., Pastorino R., Praz F., Rodes-Cabau J., Besler C., Schober A. R., Schofer J., Scotti A., Piayda K., Sievert H., Tang G. H. L., Sticchi A., Messika-Zeitoun D., Thiele H., Schlotter F., von Bardeleben R. S., Webb J., Dreyfus J., Windecker S., Leon M., Maisano F., Metra M., Taramasso M., Adamo, M, Russo, G, Pagnesi, M, Pancaldi, E, Alessandrini, H, Andreas, M, Badano, L, Braun, D, Connelly, K, Denti, P, Estevez-Loureiro, R, Fam, N, Gavazzoni, M, Hahn, R, Harr, C, Hausleiter, J, Himbert, D, Kalbacher, D, Ho, E, Latib, A, Lubos, E, Ludwig, S, Lupi, L, Lurz, P, Monivas, V, Nickenig, G, Pedicino, D, Pedrazzini, G, Pozzoli, A, Marafon, D, Pastorino, R, Praz, F, Rodes-Cabau, J, Besler, C, Schober, A, Schofer, J, Scotti, A, Piayda, K, Sievert, H, Tang, G, Sticchi, A, Messika-Zeitoun, D, Thiele, H, Schlotter, F, von Bardeleben, R, Webb, J, Dreyfus, J, Windecker, S, Leon, M, Maisano, F, Metra, M, Taramasso, M, Adamo M., Russo G., Pagnesi M., Pancaldi E., Alessandrini H., Andreas M., Badano L. P., Braun D., Connelly K. A., Denti P., Estevez-Loureiro R., Fam N., Gavazzoni M., Hahn R. T., Harr C., Hausleiter J., Himbert D., Kalbacher D., Ho E., Latib A., Lubos E., Ludwig S., Lupi L., Lurz P., Monivas V., Nickenig G., Pedicino D., Pedrazzini G., Pozzoli A., Marafon D. P., Pastorino R., Praz F., Rodes-Cabau J., Besler C., Schober A. R., Schofer J., Scotti A., Piayda K., Sievert H., Tang G. H. L., Sticchi A., Messika-Zeitoun D., Thiele H., Schlotter F., von Bardeleben R. S., Webb J., Dreyfus J., Windecker S., Leon M., Maisano F., Metra M., and Taramasso M.

Abstract

Background: Data on the prognostic role of the TRI-SCORE in patients undergoing transcatheter tricuspid valve intervention (TTVI) are limited. Objectives: The aim of this study was to evaluate the performance of the TRI-SCORE in predicting outcomes of patients undergoing TTVI. Methods: TriValve (Transcatheter Tricuspid Valve Therapies) is a large multicenter multinational registry including patients undergoing TTVI. The TRI-SCORE is a risk model recently proposed to predict in-hospital mortality after tricuspid valve surgery. The TriValve population was stratified based on the TRI-SCORE tertiles. The outcomes of interest were all-cause death and all-cause death or heart failure hospitalization. Procedural complications and changes in NYHA functional class were also reported. Results: Among the 634 patients included, 223 patients (35.2%) had a TRI-SCORE between 0 and 5, 221 (34.8%) had 6 or 7, and 190 (30%) had ≥8 points. Postprocedural blood transfusion, acute kidney injury, new atrial fibrillation, and in-hospital mortality were more frequent in the highest TRI-SCORE tertile. Postprocedure length of stay increased with a TRI-SCORE increase. A TRI-SCORE ≥8 was associated with an increased risk of 30-day all-cause mortality and all-cause mortality and the composite endpoint assessed at a median follow-up of 186 days (OR: 3.00; 95% CI: 1.38-6.55; HR: 2.17; 95% CI: 1.78-4.13; HR: 2.08, 95% CI: 1.57-2.74, respectively) even after adjustment for procedural success and EuroSCORE II or Society of Thoracic Surgeons Predicted Risk of Mortality. The NYHA functional class improved across all TRI-SCORE values. Conclusions: In the TriValve registry, the TRI-SCORE has a suboptimal performance in predicting clinical outcomes. However, a TRISCORE ≥8 is associated with an increased risk of clinical events and a lack of prognostic benefit after successful TTVI.

Published
2024

4. Characteristics and outcomes of patients with atrial versus ventricular secondary tricuspid regurgitation undergoing tricuspid transcatheter edge-to-edge repair - Results from the TriValve registry

Author

Russo, G, Badano, L, Adamo, M, Alessandrini, H, Andreas, M, Braun, D, Connelly, K, Denti, P, Estevez-Loureiro, R, Fam, N, Gavazzoni, M, Hahn, R, Harr, C, Hausleiter, J, Himbert, D, Kalbacher, D, Ho, E, Latib, A, Lubos, E, Ludwig, S, Lurz, P, Monivas, V, Nickenig, G, Pedicino, D, Pedrazzini, G, Pozzoli, A, Marafon, D, Pastorino, R, Praz, F, Rodes-Cabau, J, Besler, C, Schofer, J, Scotti, A, Piayda, K, Sievert, H, Tang, G, Thiele, H, Schlotter, F, von Bardeleben, R, Webb, J, Windecker, S, Leon, M, Maisano, F, Metra, M, Taramasso, M, Connelly, KA, Hahn, RT, Marafon, DP, Tang, GHL, von Bardeleben, RS, Russo, G, Badano, L, Adamo, M, Alessandrini, H, Andreas, M, Braun, D, Connelly, K, Denti, P, Estevez-Loureiro, R, Fam, N, Gavazzoni, M, Hahn, R, Harr, C, Hausleiter, J, Himbert, D, Kalbacher, D, Ho, E, Latib, A, Lubos, E, Ludwig, S, Lurz, P, Monivas, V, Nickenig, G, Pedicino, D, Pedrazzini, G, Pozzoli, A, Marafon, D, Pastorino, R, Praz, F, Rodes-Cabau, J, Besler, C, Schofer, J, Scotti, A, Piayda, K, Sievert, H, Tang, G, Thiele, H, Schlotter, F, von Bardeleben, R, Webb, J, Windecker, S, Leon, M, Maisano, F, Metra, M, Taramasso, M, Connelly, KA, Hahn, RT, Marafon, DP, Tang, GHL, and von Bardeleben, RS

Abstract

Aim Functional or secondary tricuspid regurgitation (STR) is the most common phenotype of tricuspid regurgitation (TR) with atrial STR (ASTR) and ventricular STR (VSTR) being recently identified as two distinct entities. Data on tricuspid transcatheter edge-to-edge repair (T-TEER) in patients with STR according to phenotype (i.e. ASTR vs. VSTR) are lacking. The aim of this study was to assess characteristics and outcomes of patients with ASTR versus VSTR undergoing T-TEER. Methods and results Patients with STR undergoing T-TEER were selected from the Transcatheter Tricuspid Valve Therapies (TriValve) registry. ASTR was defined by (i) left ventricular ejection fraction >= 50%, (ii) atrial fibrillation, and (iii) systolic pulmonary artery pressure <50 mmHg. Patients not matching these criteria were classified as VSTR. Patients with primary TR and cardiac implantable electronic device were excluded. Key endpoints included procedural success and survival at follow-up. A total of 298 patients were enrolled in the study: 65 (22%) with ASTR and 233 (78%) with VSTR. Procedural success was similar in the two groups (80% vs. 83% for ASTR vs. VSTR, p = 0.56) and TEER was effective in reducing TR in both groups (from 97% of patients with baseline TR >= 3+ to 23% in ASTR and to 15% in VSTR, all p = 0.001). At 12-month follow-up, survival was significantly higher in the ASTR versus VSTR cohort (91% vs. 72%, log-rank p = 0.02), with VSTR being an independent predictor of mortality at multivariable analysis (hazard ratio 4.75). Conclusions In a real-world, multicentre registry, T-TEER was effective in reducing TR grade in both ASTR and VSTR. At 12-month follow-up, ASTR showed better survival than VSTR.

Published
2023

9. Late Outcomes of Transcatheter Aortic Valve Replacement in High-Risk Patients: The FRANCE-2 Registry

Author

Gilard, M., Eltchaninoff, H., Donzeau-Gouge, P., Chevreul, K., Fajadet, J., Leprince, P., Leguerrier, A., Lievre, M., Prat, A., Teiger, E., Lefevre, T., Tchetche, D., Carrie, D., Himbert, D., Albat, B., Cribier, A., Sudre, A., Blanchard, D., Rioufol, G., Collet, F., Houel, R., Dos Santos, P., Meneveau, N., Ghostine, S., Manigold, T., Guyon, P., Grisoli, D., Le Breton, H., Delpine, S., Didier, R., Favereau, X., Souteyrand, G., Ohlmann, P., Doisy, V., Grollier, G., Gommeaux, A., Claudel, J. -P., Bourlon, F., Bertrand, B., Laskar, M., Iung, B., Bertrand, M., Cassagne, J., Boschat, J., Lusson, J. R., Mathieu, P., Logeais, Y., Bessou, J. -P., Chevalier, B., Farge, A., Garot, P., Hovasse, T., Morice, M. C., Romano, M., Gouge, P. D., Vahdat, O., Farah, B., Dumonteil, N., Fournial, G., Marcheix, B., Nataf, P., Vahanian, A., Leclercq, F., Piot, C., Schmutz, L., Aubas, P., du Cailar, A., Dubar, A., Durrleman, N., Fargosz, F., Levy, G., Maupas, E., Rivalland, F., Robert, G., Tron, C., Juthier, F., Modine, T., Van Belle, E., Banfi, C., Sallerin, T., Bar, O., Barbey, C., Chassaing, S., Chatel, D., Le Page, O., Tauran, A., Cao, D., Dauphin, R., Durand de Gevigney, G., Finet, G., Jegaden, O., Obadia, J. -F., Beygui, F., Collet, J. -P., Pavie, A., Pecheux, Bayet, Vaillant, A., Vicat, J., Wittenberg, O., Joly, P., Rosario, R., Bergeron, P., Bille, J., Gelisse, R., Couetil, J. -P., Dubois Rande, J. -L., Hayat, D., Fougeres, E., Monin, J. -L., Mouillet, G., Arsac, F., Choukroun, E., Dijos, M., Guibaud, J. -P., Leroux, L., Elia, N., Descotes, Genon, Chocron, S., Schiele, F., Caussin, C., Azmoun, A., Nottin, R., Tirouvanziam, A., Crochet, D., Gaudin, R., Roussel, J. -C., Bonnet, N., Digne, F., Mesnidrey, P., Royer, T., Stratiev, V., Bonnet, J. -L., Cuisset, T., Abouliatim, I., Bedossa, M., Boulmier, D., Verhoye, J. P., Delepine, S., Debrux, J. -L., Furber, A., Pinaud, F., Bezon, E., Choplain, J. -N., Bical, O., Dambrin, G., Deleuze, P., Jegou, A., Lusson, J. -R., Azarnouch, K., Durel, N., Innorta, A., Lienhart, Y., Roriz, R., Staat, P., Fabiani, J. -N., Lafont, A., Zegdi, R., Heudes, D., Kindo, M., Mazzucotelli, J. -P., Zupan, M., Ivascau, C., Lognone, T., Massetti, M., Sabatier, R., Huret, B., Hochart, P., Pecheux, Bouchayer, D., Gabrielle, F., Pelissier, F., Tremeau, G., Dreyfus, G., Eker, A., Habib, Y., Hugues, N., Mialhe, C., Chavanon, O., Porcu, P., Vanzetto, G., Banfi C., Massetti M. (ORCID:0000-0002-7100-8478), Gilard, M., Eltchaninoff, H., Donzeau-Gouge, P., Chevreul, K., Fajadet, J., Leprince, P., Leguerrier, A., Lievre, M., Prat, A., Teiger, E., Lefevre, T., Tchetche, D., Carrie, D., Himbert, D., Albat, B., Cribier, A., Sudre, A., Blanchard, D., Rioufol, G., Collet, F., Houel, R., Dos Santos, P., Meneveau, N., Ghostine, S., Manigold, T., Guyon, P., Grisoli, D., Le Breton, H., Delpine, S., Didier, R., Favereau, X., Souteyrand, G., Ohlmann, P., Doisy, V., Grollier, G., Gommeaux, A., Claudel, J. -P., Bourlon, F., Bertrand, B., Laskar, M., Iung, B., Bertrand, M., Cassagne, J., Boschat, J., Lusson, J. R., Mathieu, P., Logeais, Y., Bessou, J. -P., Chevalier, B., Farge, A., Garot, P., Hovasse, T., Morice, M. C., Romano, M., Gouge, P. D., Vahdat, O., Farah, B., Dumonteil, N., Fournial, G., Marcheix, B., Nataf, P., Vahanian, A., Leclercq, F., Piot, C., Schmutz, L., Aubas, P., du Cailar, A., Dubar, A., Durrleman, N., Fargosz, F., Levy, G., Maupas, E., Rivalland, F., Robert, G., Tron, C., Juthier, F., Modine, T., Van Belle, E., Banfi, C., Sallerin, T., Bar, O., Barbey, C., Chassaing, S., Chatel, D., Le Page, O., Tauran, A., Cao, D., Dauphin, R., Durand de Gevigney, G., Finet, G., Jegaden, O., Obadia, J. -F., Beygui, F., Collet, J. -P., Pavie, A., Pecheux, Bayet, Vaillant, A., Vicat, J., Wittenberg, O., Joly, P., Rosario, R., Bergeron, P., Bille, J., Gelisse, R., Couetil, J. -P., Dubois Rande, J. -L., Hayat, D., Fougeres, E., Monin, J. -L., Mouillet, G., Arsac, F., Choukroun, E., Dijos, M., Guibaud, J. -P., Leroux, L., Elia, N., Descotes, Genon, Chocron, S., Schiele, F., Caussin, C., Azmoun, A., Nottin, R., Tirouvanziam, A., Crochet, D., Gaudin, R., Roussel, J. -C., Bonnet, N., Digne, F., Mesnidrey, P., Royer, T., Stratiev, V., Bonnet, J. -L., Cuisset, T., Abouliatim, I., Bedossa, M., Boulmier, D., Verhoye, J. P., Delepine, S., Debrux, J. -L., Furber, A., Pinaud, F., Bezon, E., Choplain, J. -N., Bical, O., Dambrin, G., Deleuze, P., Jegou, A., Lusson, J. -R., Azarnouch, K., Durel, N., Innorta, A., Lienhart, Y., Roriz, R., Staat, P., Fabiani, J. -N., Lafont, A., Zegdi, R., Heudes, D., Kindo, M., Mazzucotelli, J. -P., Zupan, M., Ivascau, C., Lognone, T., Massetti, M., Sabatier, R., Huret, B., Hochart, P., Pecheux, Bouchayer, D., Gabrielle, F., Pelissier, F., Tremeau, G., Dreyfus, G., Eker, A., Habib, Y., Hugues, N., Mialhe, C., Chavanon, O., Porcu, P., Vanzetto, G., Banfi C., and Massetti M. (ORCID:0000-0002-7100-8478)

Abstract

Background Transcatheter aortic valve replacement (TAVR) has revolutionized management of high-risk patients with severe aortic stenosis. However, survival and the incidence of severe complications have been assessed in relatively small populations and/or with limited follow-up. Objectives This report details late clinical outcome and its determinants in the FRANCE-2 (FRench Aortic National CoreValve and Edwards) registry. Methods The FRANCE-2 registry prospectively included all TAVRs performed in France. Follow-up was scheduled at 30 days, at 6 months, and annually from 1 to 5 years. Standardized VARC (Valve Academic Research Consortium) outcome definitions were used. Results A total of 4,201 patients were enrolled between January 2010 and January 2012 in 34 centers. Approaches were transarterial (transfemoral 73%, transapical 18%, subclavian 6%, and transaortic or transcarotid 3%) or, in 18% of patients, transapical. Median follow-up was 3.8 years. Vital status was available for 97.2% of patients at 3 years. The 3-year all-cause mortality was 42.0% and cardiovascular mortality was 17.5%. In a multivariate model, predictors of 3-year all-cause mortality were male sex (p < 0.001), low body mass index, (p < 0.001), atrial fibrillation (p < 0.001), dialysis (p < 0.001), New York Heart Association functional class III or IV (p < 0.001), higher logistic EuroSCORE (p < 0.001), transapical or subclavian approach (p < 0.001 for both vs. transfemoral approach), need for permanent pacemaker implantation (p = 0.02), and post-implant periprosthetic aortic regurgitation grade ≥2 of 4 (p < 0.001). Severe events according to VARC criteria occurred mainly during the first month and subsequently in <2% of patients/year. Mean gradient, valve area, and residual aortic regurgitation were stable during follow-up. Conclusions The FRANCE-2 registry represents the largest database available on late results of TAVR. Late mortality is largely related to noncardiac

Published
2016

10. Comparison of vascular closure devices for access site closure after transfemoral aortic valve implantation

Author

Barbash, I, Barbanti, M, Webb, J, Molina Martin De Nicolas, J, Abramowitz, Y, Latib, A, Nguyen, C, Deuschl, F, Segev, A, Sideris, K, Buccheri, S, Simonato, M, DELLA ROSA, F, Tamburino, C, Jilaihawi, H, Miyazaki, T, Himbert, D, Schofer, N, Guetta, V, Bleiziffer, S, Tchetche, D, Immè, S, Makkar, R, Vahanian, A, Treede, H, Lange, R, Colombo, A, Dvir, D, Dvir, D., DELLA ROSA, FRANCESCO, Barbash, I, Barbanti, M, Webb, J, Molina Martin De Nicolas, J, Abramowitz, Y, Latib, A, Nguyen, C, Deuschl, F, Segev, A, Sideris, K, Buccheri, S, Simonato, M, DELLA ROSA, F, Tamburino, C, Jilaihawi, H, Miyazaki, T, Himbert, D, Schofer, N, Guetta, V, Bleiziffer, S, Tchetche, D, Immè, S, Makkar, R, Vahanian, A, Treede, H, Lange, R, Colombo, A, Dvir, D, Dvir, D., and DELLA ROSA, FRANCESCO

Abstract

Background The majority of transcatheter aortic valve implantation (TAVI) procedures are currently performed by percutaneous transfemoral approach. The potential contribution of the type of vascular closure device to the incidence of vascular complications is not clear. Aim To compare the efficacy of a Prostar XL-vs. Perclose ProGlide-based vascular closure strategy. Methods The ClOsure device iN TRansfemoral aOrtic vaLve implantation (CONTROL) multi-center study included 3138 consecutive percutaneous transfemoral TAVI patients, categorized according to vascular closure strategy: Prostar XL-(Prostar group) vs. Perclose ProGlide-based vascular closure strategy (ProGlide group). Propensity-score matching was used to assemble a cohort of patients with similar baseline characteristics. Results Propensity matching identified 944 well-matched patients (472 patient pairs). Composite primary end point of major vascular complications or in-hospital mortality occurred more frequently in Prostar group when compared with ProGlide group (9.5 vs. 5.1%, P = 0.016), and was driven by higher rates of major vascular complication (7.4 vs. 1.9%, P < 0.001) in the Prostar group. However, in-hospital mortality was similar between groups (4.9 vs. 3.5%, P = 0.2). Femoral artery stenosis occurred less frequently in the Prostar group (3.4 vs. 0.5%, P = 0.004), but overall, Prostar use was associated with higher rates of major bleeding (16.7 vs. 3.2%, P < 0.001), acute kidney injury (17.6 vs. 4.4%, P < 0.001) and with longer hospital stay (median 6 vs. 5 days, P = 0.007). Conclusions Prostar XL-based vascular closure in transfemoral TAVI procedures is associated with higher major vascular complication rates when compared with ProGlide; however, in-hospital mortality is similar with both devices.

Published
2015

11. Registry of transcatheter aortic-valve implantation in high-risk patients

Author

Gilard, M., Eltchaninoff, H., Iung, B., Chevreul, K., Fajadet, J., Leprince, P., Leguerrier, A., Lievre, M., Prat, A., Teiger, E., Lefevre, T., Himbert, D., Tchetche, D., Carriè, D., Albat, B., Cribier, A., Rioufol, G., Sudre, A., Blanchard, D., Collet, F., Dos Santos, P., Meneveau, N., Tirouvanziam, A., Caussin, C., Guyon, P., Boschat, J., Le Breton, H., Collart, F., Houel, R., Delpine, S., Souteyrand, G., Favereau, X., Ohlmann, P., Doisy, V., Grollier, G., Gommeaux, A., Massetti, Massimo, Massetti, Massimo (ORCID:0000-0002-7100-8478), Gilard, M., Eltchaninoff, H., Iung, B., Chevreul, K., Fajadet, J., Leprince, P., Leguerrier, A., Lievre, M., Prat, A., Teiger, E., Lefevre, T., Himbert, D., Tchetche, D., Carriè, D., Albat, B., Cribier, A., Rioufol, G., Sudre, A., Blanchard, D., Collet, F., Dos Santos, P., Meneveau, N., Tirouvanziam, A., Caussin, C., Guyon, P., Boschat, J., Le Breton, H., Collart, F., Houel, R., Delpine, S., Souteyrand, G., Favereau, X., Ohlmann, P., Doisy, V., Grollier, G., Gommeaux, A., Massetti, Massimo, and Massetti, Massimo (ORCID:0000-0002-7100-8478)

Abstract

Transcatheter aortic-valve implantation (TAVI) is an emerging intervention for the treatment of high-risk patients with severe aortic stenosis and coexisting illnesses. We report the results of a prospective multicenter study of the French national transcatheter aortic-valve implantation registry, FRANCE 2.

Published
2012

12. One year follow-up of the multi-centre European PARTNER transcatheter heart valve study

Author

Lefèvre, T. (Thierry), Kappetein, A.P. (Arie Pieter), Wolner, E. (Ernst), Nataf, P. (Patrick), Thomas, M. (Martyn), Schächinger, V. (Volker), Bruyne, B. (Bernard) de, Eltchaninoff, H. (Hélène), Thielmann, M. (Matthias), Himbert, D. (Dominique), Romano, M. (Mauro), Serruys, P.W.J.C. (Patrick), Wimmer-Greinecker, G. (Gerhard), Lefèvre, T. (Thierry), Kappetein, A.P. (Arie Pieter), Wolner, E. (Ernst), Nataf, P. (Patrick), Thomas, M. (Martyn), Schächinger, V. (Volker), Bruyne, B. (Bernard) de, Eltchaninoff, H. (Hélène), Thielmann, M. (Matthias), Himbert, D. (Dominique), Romano, M. (Mauro), Serruys, P.W.J.C. (Patrick), and Wimmer-Greinecker, G. (Gerhard)

Abstract

BackgroundTranscatheter aortic valve implantation (TAVI) has emerged as a new therapeutic option in high-risk patients with severe aortic stenosis.AimsPARTNER EU is the first study to evaluate prospectively the procedural and mid-term outcomes of transfemoral (TF) or transapical (TA) implantation of the Edwards SAPIEN® valve involving a multi-disciplinary approach.Methods and resultsPrimary safety endpoints were 30 days and 6 months mortality. Primary efficacy endpoints were haemodynamic and functional improvement at 12 months. One hundred and thirty patients (61 TF, 69 TA), aged 82.1 ± 5.5 years were included. TA patients had higher logistic EuroSCORE (33.8 vs. 25.7, P <0.0005) and more peripheral disease (49.3 vs. 16.4, P< 0.0001). Procedures were aborted in four TA (5.8) and six TF cases (9.8). Valve implantation was successful in the remaining patients in 95.4 and 96.4, respectively. Thirty days and 6 months survival were 81.2 and 58.0 (TA) and 91.8 and 90.2 (TF). In both groups, mean aortic gradient decreased from 46.9 ± 18.1 to 10.9 ± 5.4 mmHg 6 months post-TAVI. In total, 78.1 and 84.8 of patients experienced significant improvement in New York Heart Association (NYHA) class, whereas 73.9 and 72.7 had improved Kansas City Cardiomyopathy Questionnaire (KCCQ) scores in TA and TF cohorts, respectively.ConclusionThis first team-based multi-centre European TAVI registry shows promising results in high-risk patients treated by TF or TA delivery. Survival rates differ significantly between TF and TA groups and probably reflect the higher risk profile of the TA cohort. Optimal patient screening, approach selection, and device refinement may improve outcomes.

Published
2011
Full Text
View/download PDF

13. One year follow-up of the multi-centre European PARTNER transcatheter heart valve study

Author

Lefevre, T, Kappetein, Arie-Pieter, Wolner, E, Nataf, P, Thomas, M, Schachinger, V, de Bruyne, B, Eltchaninoff, H, Thielmann, M, Himbert, D, Romano, M, Serruys, PWJC (Patrick), Wimmer-Greinecker, G, Lefevre, T, Kappetein, Arie-Pieter, Wolner, E, Nataf, P, Thomas, M, Schachinger, V, de Bruyne, B, Eltchaninoff, H, Thielmann, M, Himbert, D, Romano, M, Serruys, PWJC (Patrick), and Wimmer-Greinecker, G

Abstract

Background Transcatheter aortic valve implantation (TAVI) has emerged as a new therapeutic option in high-risk patients with severe aortic stenosis. Aims PARTNER EU is the first study to evaluate prospectively the procedural and mid-term outcomes of transfemoral (TF) or transapical (TA) implantation of the Edwards SAPIEN (R) valve involving a multi-disciplinary approach. Methods and results Primary safety endpoints were 30 days and 6 months mortality. Primary efficacy endpoints were haemodynamic and functional improvement at 12 months. One hundred and thirty patients (61 TF, 69 TA), aged 82.1 +/- 5.5 years were included. TA patients had higher logistic EuroSCORE (33.8 vs. 25.7%, P = 0.0005) and more peripheral disease (49.3 vs. 16.4%, P < 0.0001). Procedures were aborted in four TA (5.8%) and six TF cases (9.8%). Valve implantation was successful in the remaining patients in 95.4 and 96.4%, respectively. Thirty days and 6 months survival were 81.2 and 58.0% (TA) and 91.8 and 90.2% (TF). In both groups, mean aortic gradient decreased from 46.9 +/- 18.1 to 10.9 +/- 5.4 mmHg 6 months post-TAVI. In total, 78.1 and 84.8% of patients experienced significant improvement in New York Heart Association (NYHA) class, whereas 73.9 and 72.7% had improved Kansas City Cardiomyopathy Questionnaire (KCCQ) scores in TA and TF cohorts, respectively. Conclusion This first team-based multi-centre European TAVI registry shows promising results in high-risk patients treated by TF or TA delivery. Survival rates differ significantly between TF and TA groups and probably reflect the higher risk profile of the TA cohort. Optimal patient screening, approach selection, and device refinement may improve outcomes.

Published
2011

14. Vectorcardiographic monitoring to assess early vessel patency after reperfusion therapy for acute myocardial infarction

Author

Dellborg, M., Steg, P.G. (Philippe Gabriel), Simoons, M.L. (Maarten), Dietz, R., Sen, S. (Semi), Lotze, U. (Ulrich), Himbert, D., Svensson, A.M., Swedberg, K. (Karl), Brand, M.J.B.M. (Marcel) van den, Wieken, L.R. (Ron) van der, Hauck, S., Dellborg, M., Steg, P.G. (Philippe Gabriel), Simoons, M.L. (Maarten), Dietz, R., Sen, S. (Semi), Lotze, U. (Ulrich), Himbert, D., Svensson, A.M., Swedberg, K. (Karl), Brand, M.J.B.M. (Marcel) van den, Wieken, L.R. (Ron) van der, and Hauck, S.

Abstract

Reperfusion therapy has lowered mortality in patients suffering from acute myocardial infarction. Failure to reperfuse is associated with an increased short- and long-term mortality. In a prospective study we used dynamic vectorcardiography to monitor 96 patients with acute myocardial infarction treated with reperfusion therapy to non-invasively assess coronary patency. The results from continuous monitoring were compared to those obtained from angiography. By using trend-analysis of QRS vector difference and ST vector magnitude, we were able to correctly identify 58 of the 70 patients (83%) with a reperfused infarct-related artery, and 19 of the 26 patients (73%) with a persistently occluded artery demonstrated at an early angiogram (diagnostic accuracy 80%). In patients with high-grade collateral flow to the infarct-related area, the results of the vectorcardiographic monitoring and of angiography showed the largest disagreement, whereas the accuracy of vectorcardiographic monitoring was high: 88% among patients without collaterals. The present results suggest that QRS complex and ST segment vectorcardiographic monitoring is a useful tool for assessing early coronary artery patency, and that dynamic vectorcardiography may help in identifying candidates for emergency coronary angiography.

Published
1995

Catalog

Books, media, physical & digital resources
See catalog results